Skip to main
ACAD

ACADIA Pharma (ACAD) Stock Forecast & Price Target

ACADIA Pharma (ACAD) Analyst Ratings

Based on 19 analyst ratings
Buy
Strong Buy 37%
Buy 42%
Hold 16%
Sell 0%
Strong Sell 5%

Bulls say

ACADIA Pharmaceuticals Inc. has demonstrated strong commercial execution and revenue growth, particularly with its pivotal products, NUPLAZID and DAYBUE, which are positioned to address significant unmet needs in neurological and rare diseases. The company projects combined net sales of approximately $1.7 billion by 2028, bolstered by robust year-over-year growth in DAYBUE, achieving $110 million in the latest quarter, exceeding consensus forecasts. Additionally, ongoing expansion of its field force and positive developments in intellectual property are expected to reinforce NUPLAZID revenue stability, supporting a positive trajectory for the company's financial outlook.

Bears say

ACADIA Pharmaceuticals faces significant challenges that contribute to a negative outlook on its stock, including the negative trend vote from the CHMP for trofinetide, which delays potential revenue from its EU launch and raises doubts about the product's market opportunity. Furthermore, key risks include uncertainties surrounding intellectual property, potential declines in reimbursement rates, and a slowing uptake of its core products, Nuplazid and Daybue, as well as existing safety concerns that could hamper market acceptance. Additionally, high dropout rates in clinical studies and mixed expert feedback regarding the efficacy of its therapies suggest that the company may struggle to demonstrate the meaningful benefits that would support robust market demand.

ACADIA Pharma (ACAD) has been analyzed by 19 analysts, with a consensus rating of Buy. 37% of analysts recommend a Strong Buy, 42% recommend Buy, 16% suggest Holding, 0% advise Selling, and 5% predict a Strong Sell.

This aggregate rating is based on analysts' research of ACADIA Pharma and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About ACADIA Pharma (ACAD) Forecast

Analysts have given ACADIA Pharma (ACAD) a Buy based on their latest research and market trends.

According to 19 analysts, ACADIA Pharma (ACAD) has a Buy consensus rating as of Apr 6, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $31.32, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $31.32, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

ACADIA Pharma (ACAD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.